Home » Prometheus Licenses Colal-Pred From Alizyme
Prometheus Licenses Colal-Pred From Alizyme
Prometheus Laboratories Inc., a specialty pharmaceutical company, announced that it has entered into an exclusive license agreement to develop and commercialize Colal-Pred for gastrointestinal diseases or other applications in North America from Alizyme Therapeutics Limited, a wholly owned subsidiary of Alizyme plc.
Earthtimes
Earthtimes
Upcoming Events
-
07May
-
14May
-
30May